Cargando…

A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design

BACKGROUND: Friedreich's ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet reported frataxin protein and mRNA levels in a large coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Saccà, Francesco, Puorro, Giorgia, Antenora, Antonella, Marsili, Angela, Denaro, Alessandra, Piro, Raffaele, Sorrentino, Pierpaolo, Pane, Chiara, Tessa, Alessandra, Brescia Morra, Vincenzo, Cocozza, Sergio, De Michele, Giuseppe, Santorelli, Filippo M., Filla, Alessandro
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055871/
https://www.ncbi.nlm.nih.gov/pubmed/21412413
http://dx.doi.org/10.1371/journal.pone.0017627
_version_ 1782200153077186560
author Saccà, Francesco
Puorro, Giorgia
Antenora, Antonella
Marsili, Angela
Denaro, Alessandra
Piro, Raffaele
Sorrentino, Pierpaolo
Pane, Chiara
Tessa, Alessandra
Brescia Morra, Vincenzo
Cocozza, Sergio
De Michele, Giuseppe
Santorelli, Filippo M.
Filla, Alessandro
author_facet Saccà, Francesco
Puorro, Giorgia
Antenora, Antonella
Marsili, Angela
Denaro, Alessandra
Piro, Raffaele
Sorrentino, Pierpaolo
Pane, Chiara
Tessa, Alessandra
Brescia Morra, Vincenzo
Cocozza, Sergio
De Michele, Giuseppe
Santorelli, Filippo M.
Filla, Alessandro
author_sort Saccà, Francesco
collection PubMed
description BACKGROUND: Friedreich's ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet reported frataxin protein and mRNA levels in a large cohort of FRDA patients, carriers and controls. METHODOLOGY/PRINCIPAL FINDINGS: We enrolled 24 patients with classic FRDA phenotype (cFA), 6 late onset FRDA (LOFA), all homozygous for GAA expansion, 5 pFA cases who harbored the GAA expansion in compound heterozygosis with FXN point mutations (namely, p.I154F, c.482+3delA, p.R165P), 33 healthy expansion carriers, and 29 healthy controls. DNA was genotyped for GAA expansion, mRNA/FXN was quantified in real-time, and frataxin protein was measured using lateral-flow immunoassay in peripheral blood mononuclear cells (PBMCs). Mean residual levels of frataxin, compared to controls, were 35.8%, 65.6%, 33%, and 68.7% in cFA, LOFA, pFA and healthy carriers, respectively. Comparison of both cFA and pFA with controls resulted in 100% sensitivity and specificity, but there was overlap between LOFA, carriers and controls. Frataxin levels correlated inversely with GAA1 and GAA2 expansions, and directly with age at onset. Messenger RNA expression was reduced to 19.4% in cFA, 50.4% in LOFA, 52.7% in pFA, 53.0% in carriers, as compared to controls (p<0.0001). mRNA levels proved to be diagnostic when comparing cFA with controls resulting in 100% sensitivity and specificity. In cFA and LOFA patients mRNA levels correlated directly with protein levels and age at onset, and inversely with GAA1 and GAA2. CONCLUSION/SIGNIFICANCE: We report the first explorative study on combined frataxin and mRNA levels in PBMCs from a cohort of FRDA patients, carriers and healthy individuals. Lateral-flow immunoassay differentiated cFA and pFA patients from controls, whereas determination of mRNA in q-PCR was sensitive and specific only in cFA.
format Text
id pubmed-3055871
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30558712011-03-16 A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design Saccà, Francesco Puorro, Giorgia Antenora, Antonella Marsili, Angela Denaro, Alessandra Piro, Raffaele Sorrentino, Pierpaolo Pane, Chiara Tessa, Alessandra Brescia Morra, Vincenzo Cocozza, Sergio De Michele, Giuseppe Santorelli, Filippo M. Filla, Alessandro PLoS One Research Article BACKGROUND: Friedreich's ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet reported frataxin protein and mRNA levels in a large cohort of FRDA patients, carriers and controls. METHODOLOGY/PRINCIPAL FINDINGS: We enrolled 24 patients with classic FRDA phenotype (cFA), 6 late onset FRDA (LOFA), all homozygous for GAA expansion, 5 pFA cases who harbored the GAA expansion in compound heterozygosis with FXN point mutations (namely, p.I154F, c.482+3delA, p.R165P), 33 healthy expansion carriers, and 29 healthy controls. DNA was genotyped for GAA expansion, mRNA/FXN was quantified in real-time, and frataxin protein was measured using lateral-flow immunoassay in peripheral blood mononuclear cells (PBMCs). Mean residual levels of frataxin, compared to controls, were 35.8%, 65.6%, 33%, and 68.7% in cFA, LOFA, pFA and healthy carriers, respectively. Comparison of both cFA and pFA with controls resulted in 100% sensitivity and specificity, but there was overlap between LOFA, carriers and controls. Frataxin levels correlated inversely with GAA1 and GAA2 expansions, and directly with age at onset. Messenger RNA expression was reduced to 19.4% in cFA, 50.4% in LOFA, 52.7% in pFA, 53.0% in carriers, as compared to controls (p<0.0001). mRNA levels proved to be diagnostic when comparing cFA with controls resulting in 100% sensitivity and specificity. In cFA and LOFA patients mRNA levels correlated directly with protein levels and age at onset, and inversely with GAA1 and GAA2. CONCLUSION/SIGNIFICANCE: We report the first explorative study on combined frataxin and mRNA levels in PBMCs from a cohort of FRDA patients, carriers and healthy individuals. Lateral-flow immunoassay differentiated cFA and pFA patients from controls, whereas determination of mRNA in q-PCR was sensitive and specific only in cFA. Public Library of Science 2011-03-11 /pmc/articles/PMC3055871/ /pubmed/21412413 http://dx.doi.org/10.1371/journal.pone.0017627 Text en Saccà et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Saccà, Francesco
Puorro, Giorgia
Antenora, Antonella
Marsili, Angela
Denaro, Alessandra
Piro, Raffaele
Sorrentino, Pierpaolo
Pane, Chiara
Tessa, Alessandra
Brescia Morra, Vincenzo
Cocozza, Sergio
De Michele, Giuseppe
Santorelli, Filippo M.
Filla, Alessandro
A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
title A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
title_full A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
title_fullStr A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
title_full_unstemmed A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
title_short A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
title_sort combined nucleic acid and protein analysis in friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055871/
https://www.ncbi.nlm.nih.gov/pubmed/21412413
http://dx.doi.org/10.1371/journal.pone.0017627
work_keys_str_mv AT saccafrancesco acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT puorrogiorgia acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT antenoraantonella acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT marsiliangela acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT denaroalessandra acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT piroraffaele acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT sorrentinopierpaolo acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT panechiara acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT tessaalessandra acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT bresciamorravincenzo acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT cocozzasergio acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT demichelegiuseppe acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT santorellifilippom acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT fillaalessandro acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT saccafrancesco combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT puorrogiorgia combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT antenoraantonella combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT marsiliangela combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT denaroalessandra combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT piroraffaele combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT sorrentinopierpaolo combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT panechiara combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT tessaalessandra combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT bresciamorravincenzo combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT cocozzasergio combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT demichelegiuseppe combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT santorellifilippom combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign
AT fillaalessandro combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign